Catalogo dei prodotti della ricerca

PIZZUTI, Laura
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.492
EU - Europa 798
AS - Asia 293
AF - Africa 10
SA - Sud America 5
OC - Oceania 1
Totale 2.599
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.474
SE - Svezia 324
IT - Italia 262
SG - Singapore 119
IN - India 69
CN - Cina 52
DE - Germania 50
FI - Finlandia 43
ID - Indonesia 30
GB - Regno Unito 23
UA - Ucraina 17
CA - Canada 16
IE - Irlanda 16
BG - Bulgaria 12
RO - Romania 12
FR - Francia 11
IR - Iran 8
HK - Hong Kong 7
RU - Federazione Russa 7
TG - Togo 7
NL - Olanda 6
CH - Svizzera 4
AR - Argentina 2
BE - Belgio 2
ES - Italia 2
KZ - Kazakistan 2
SC - Seychelles 2
TH - Thailandia 2
TR - Turchia 2
AU - Australia 1
BO - Bolivia 1
CL - Cile 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
EC - Ecuador 1
EE - Estonia 1
GR - Grecia 1
HR - Croazia 1
IL - Israele 1
JP - Giappone 1
LT - Lituania 1
MX - Messico 1
PT - Portogallo 1
SK - Slovacchia (Repubblica Slovacca) 1
ZA - Sudafrica 1
Totale 2.599
Salva come PNG Salva come JPEG
Città #
Fairfield 210
Stockholm 158
Ashburn 104
Woodbridge 101
Seattle 99
Rome 98
Houston 95
Chandler 90
Wilmington 84
Cambridge 82
Singapore 80
Santa Clara 75
Princeton 41
San Paolo di Civitate 41
Helsinki 37
New York 30
Dearborn 29
Jakarta 29
Ann Arbor 25
Lawrence 25
Millbury 23
Bremen 19
Andover 16
Sacramento 16
Dublin 14
Ottawa 14
San Diego 14
Beijing 13
Milan 12
Sofia 12
Plano 11
Boston 9
Norwalk 8
Falkenstein 7
Hong Kong 7
Lomé 7
Surrey 7
Leawood 6
Los Angeles 6
Boardman 5
Bühl 5
Jacksonville 5
Phoenix 4
Zanjan 4
Deiva Marina 3
Falls Church 3
Glasgow 3
Groningen 3
Moscow 3
Torino 3
Amsterdam 2
Bengaluru 2
Birmingham 2
Bovisio-Masciago 2
Buffalo 2
Dallas 2
Edinburgh 2
Federal 2
Formello 2
Fort Worth 2
Frankfurt am Main 2
Fremont 2
Guangzhou 2
Kish 2
Latina 2
Levallois-perret 2
Livorno 2
London 2
Madrid 2
Magenta 2
Mannheim 2
Naples 2
Paris 2
Petilia Policastro 2
Redwood City 2
Santa Maria Capua Vetere 2
Shanghai 2
Shenyang 2
Toronto 2
Treviso 2
Trumbull 2
Turin 2
Venice 2
Zhengzhou 2
Almaty 1
Augusta 1
Avellino 1
Balasore 1
Bangkok 1
Berlin 1
Bern 1
Boydton 1
Bratislava 1
Brussels 1
Cadelbosco di Sopra 1
Carlentini 1
Castellana Grotte 1
Catania 1
Chengdu 1
Chieti 1
Totale 1.879
Salva come PNG Salva come JPEG
Nome #
The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial 188
The sexist behaviour of immune checkpoint inhibitors in cancer therapy? 123
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study 107
A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab 107
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 100
Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: the EverExt study 100
Long-Term Safety and Real-World Effectiveness of Trastuzumab in Breast Cancer 95
Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab 93
Metabolic determinants and anthropometric indicators impact clinical-pathological features in epithelial ovarian cancer patients 87
Cdk4/6 inhibitor treatments in patients with hormone receptor positive, her2 negative advanced breast cancer. Potential molecular mechanisms, clinical implications and future perspectives 87
"Triple positive" early breast cancer: an observational multicenter retrospective analysis of outcome 86
The impact of locoregional treatment on response to Nivolumab in advanced platinum refractory head and neck cancer: the NEED TRIAL 74
Neoadjuvant sequential docetaxel followed by high-dose epirubicin in combination with cyclophosphamide administered concurrently with trastuzumab. The DECT trial 72
Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients. A multicenter Italian experience 70
Observational study of coagulation activation in early breast cancer: development of a prognostic model based on data from the real world setting 70
Autoantibodies specific to ERa are involved in tamoxifen resistance in hormone receptor positive breast cancer 67
Non-pegylated liposomal doxorubicin-cyclophosphamide in sequential regimens with taxanes as neoadjuvant chemotherapy in breast cancer patients 66
KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden 63
Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence 63
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience 62
KEAP1 and TP53 frame genomic, evolutionary and immunological subtypes of lung adenocarcinoma with different sensitivity to immunotherapy 62
Neoadjuvant immune-checkpoint blockade in triple-negative breast cancer: current evidence and literature-based meta-analysis of randomized trials 61
Immnunohistochemical Expression and Prognostic Significance of Fatty Acid Synthase in Pancreatic Carcinoma 60
Immunotherapy in HER2-positive breast cancer. state of the art and future perspectives 58
Role of chemotherapy in vulvar cancers: time to rethink standard of care? 56
Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genes 55
null 54
null 52
COVID-19 risk in breast cancer patients receiving CDK4/6 inhibitors: literature data and a monocentric experience 48
The Role of the CDK4/6 Inhibitor Ribociclib in Locally Advanced and Oligometastatic Hormone Receptor Positive, Her2 Negative, Advanced Breast Cancer: Case Series and Review of the Literature 45
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting 43
Observational multicenter study on the prognostic relevance of coagulation activation in risk assessment and stratification in locally advanced breast cancer. Outline of the arias trial 42
Circulating hpv dna in the management of oropharyngeal and cervical cancers: current knowledge and future perspectives 38
Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1B 37
GLUT 1 receptor expression and circulating levels of fasting glucose in high grade serous ovarian cancer 34
Biomarkers of response and resistance to CDK4/6 inhibitors in breast cancer: hints from liquid biopsy and microRNA exploration 28
Burnout of health care providers during the covid-19 pandemic: Focus on medical oncologists 26
Neoadjuvant endocrine therapy in breast cancer. Current knowledge and future perspectives 25
Sexual dysfunctions in breast cancer patients. Evidence in context 24
MicroRNA-based signatures impacting clinical course and biology of ovarian cancer: a miRNOmics study 24
null 21
Prognostic relevance of neutrophil to lymphocyte ratio (Nlr) in luminal breast cancer: A retrospective analysis in the neoadjuvant setting 21
DARPP-32 and t-DARPP in the development of resistance to anti-HER2 agents. Pre-clinical evidence from the STEP study 20
Multicohort and cross-platform validation of a prognostic Wnt signature in colorectal cancer 20
MicroRNA-based signatures impacting clinical course and biology of ovarian cancer: a miRNOmics study 19
Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting 17
null 16
Risk of SARS-CoV-2 infection and disease in metastatic triple-negative breast cancer patients treated with immune checkpoint inhibitors 15
Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: the Neopearl nationwide collaborative study 14
Breast and cervical cancer in transgender men: literature review and a case report 8
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study 7
Totale 2.830
Salva come PNG Salva come JPEG
Categoria #
all - tutte 9.639
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.639
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020351 0 0 0 0 0 67 62 63 54 53 26 26
2020/2021259 33 13 14 16 4 8 2 10 28 103 25 3
2021/2022470 8 7 25 25 81 34 10 33 27 26 133 61
2022/2023599 121 114 46 43 68 47 18 46 44 10 33 9
2023/2024294 9 35 10 28 30 47 11 41 9 29 27 18
2024/2025535 174 54 57 88 118 44 0 0 0 0 0 0
Totale 2.830